Interest is growing in discussions by the Ministry of Health, Labor and Welfare’s (MHLW) new expert panel on comprehensive pharmaceutical measures. At its meeting on September 22, major trade groups made their cases to push for a re-think of the…
HOME > LATEST
LATEST
-
REGULATORY Japan OKs Additional Indications for 12 Fertility Treatments
September 20, 2022
-
BUSINESS Daiichi Sankyo Apologizes for Arrest of Employee
September 20, 2022
-
BUSINESS Shionogi Eyes EUA of COVID Pill in South Korea via Sublicense to Local Firm
September 20, 2022
-
BUSINESS Daiichi Sankyo Employee Nabbed for Killing Wife with Methanol
September 20, 2022
-
REGULATORY Moderna in Talks with Govt on Building Vaccine Plant in Japan: CEO
September 16, 2022
-
BUSINESS Asahi Kasei Bags Japan Commercial Rights for Two Sobi Treatments
September 16, 2022
-
ORGANIZATION Shionogi’s COVID Pill Might Not Be Applicable for Emergency Approval: JPMA Exec
September 16, 2022
-
ORGANIZATION JPMA Managing Director Tanaka to Retire, Ex-Chugai Official to Take Over
September 16, 2022
-
ORGANIZATION JPMA to Present Proposal on Value-Based Drug Pricing at Upcoming Panel Hearing
September 16, 2022
-
BUSINESS Kyowa Kirin Seeks Palmoplantar Pustulosis Nod for Lumicef in Japan
September 16, 2022
-
BUSINESS Insmed CEO Sees Japan as Cornerstone of APAC Strategy, Doubling of Staff in Next 2 Years
September 16, 2022
-
REGULATORY Govt’s Economic Security Panel Discusses Plan for Supply Chain Survey
September 16, 2022
-
REGULATORY MHLW to Submit Bill for Integrating Drug Supply Info in Extraordinary Diet Session: Official
September 15, 2022
-
REGULATORY Japan’s Omicron Booster Program to Get Underway on Sept. 20
September 15, 2022
-
REGULATORY MHLW to Simplify Optimal-Use Guidelines for Drugs after Reexamination Period
September 15, 2022
-
BUSINESS Novartis’s Sandimmun Faces Post-Recall Stockout, Re-Supply Expected after Late October
September 15, 2022
-
BUSINESS Moderna to Have One of Industry’s Biggest Pipelines in 5 Years, Oncology Might Make Up 30% of Sales: CEO
September 15, 2022
-
BUSINESS Eisai on Course towards 500-Billion-Yen Mark in Global Lenvima Sales as Trials Progress: Eisai Official
September 14, 2022
-
REGULATORY Contraindication Lifted for Concurrent Use of Adempas and HIV Protease Inhibitors
September 14, 2022
-
BUSINESS Lonsurf-Bevacizumab Combo Extends Survival in PIII Colorectal Cancer Trial
September 14, 2022
ページ
Healthcare in the US is a highly political topic, with one end of the political spectrum arguing for broader government-sponsored access and the other advocating for more of a free-market approach. While the US market has typically been the primary…
The average ratio of females in managerial posts at Japanese drug makers has finally reached a double-digit number, at 10.0%, a Jiho survey found. However, this is still well below a near-25% ratio logged by foreign players operating in the…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…
A total of 15 new drugs (APIs) joined the NHI price list in 2021 with peak sales forecasts topping at 10 billion yen, many of them in the area of orphan diseases and with few mega launches, according to a…